Recently, as follow-up on the SALT trial, the same authors published the SMART study results [25, 27].
Previous results from the SMART study showed that HIV/viral hepatitis co-infected persons with impaired liver function are at increased risk of death following interruption of antiretroviral therapy (ART).
The most recent renovation added smart study rooms, an enlarged computer area, new circulation areas, a tutoring center, and the nation's first double-sided Starbucks.
It is important to note that the SMART study was performed between 2002 and 2006.
The SMART study was financially supported by a grant of the UMC Utrecht, The Netherlands.
The SMART study used a scale from one to five to score the evidence [ 34].
In this study, we used data from patients enrolled in the Second Manifestations of Arterial disease (SMART) study.
This section of the diary was adapted from the 4-day activity diary used in the Eat Smart study.
For the SMART study, the left and right common carotid arteries were examined in the anterolateral, posterolateral, and mediolateral directions.
Four hundred thirteen adult renal transplant recipients visiting the outpatient clinic for their yearly check-up were asked to participate in the SMART study.
These data were generally consistent with other cohorts and post hoc analysis of the SMART study (described below), and hence were not particularly controversial.
